Via and Amitis Group take over Awakn Clinics London

Via is proud to announce that it is launching a new and exciting joint venture with UK private investment company, Amitis Group, to take over treatment provision at Awakn Clinics London.

Awakn Life Sciences Corp (Awakn) is a clinical stage biotechnology company developing therapeutics to treat addiction with a near-term focus on alcohol use disorder. In addition to research and development (R&D), Awakn operates a healthcare services business unit with clinics in the UK and Norway. 

Awakn recently announced that it will be exiting from healthcare service delivery to focus solely on biotechnology R&D.   

Following Awakn’s restructure, Via’s joint venture with Amitis Group has acquired Awakn London Limited, a central London clinic trading as Awakn Clinics London. Via is now leading all treatments and therapies at the Awakn Clinics London with implementation starting from 5 July 2023.  

The ground-breaking treatments involve the use of ketamine, in a controlled and supervised setting as part of a range of psychotherapy sessions, to help people access and process difficult emotions and experiences. It has shown positive results in managing a range of mental health conditions, including depression, anxiety, post-traumatic stress disorder (PTSD), and alcohol relapse prevention.   

Anna Whitton, CEO of Via said: “This is an incredible opportunity for Via to be at the cutting-edge of new therapeutic treatments and is a significant step forward in the potential to bring these treatments into the mainstream, with a view to facilitate access to people most in need. We’re excited about this partnership, the opportunity to continue engaging with the innovation, impact and research journey, and also collaborating with partners and colleagues in the drug and alcohol sector.” 

Dr Arun Dhandayudham, Executive Medical Director at Via and Chief Medical Officer at Awakn added: ‘Ketamine-assisted psychotherapy is a significant development in the field of mental health and addictions treatment, and we’re thrilled to be a part of it. As medical professionals, it’s our responsibility to ensure that people have access to the most effective and safe treatments available. We look forward to expanding the availability of this treatment and to continue to research its potential benefits and risks. This treatment has shown promising results in clinical trials and offers hope to those who have not found relief from traditional therapies. I’m very confident that bringing Awakn Clinics London under the Via umbrella will be a powerful way to drive this treatment forward and give so many people fresh hope.” 

Roz Gittins,Director of Care Standards and Practice Improvement at Via and a member of Drug Science’s Medical Psychedelic Working Group commented: “This is a really exciting time for Via to be leading the way on the use of medical psychedelics in clinical practice. I’m looking forward to support leading on this joint venture to enable greater access and improved research in the management of mental health conditions.” 

Dr Rachel Britton, Clinical Lead at Via and Consultant Pharmacist at Awakn said: “I’m joining Via at an exciting time as we look to bring psychedelic medicine towards the mainstream. I’ve been fortunate to work with Awakn from the very beginning, establishing the first clinic of its kind in the UK. I look forward to working with the staff teams to build momentum and offer an alternative where existing therapies have failed.” 

Anthony Tennyson, CEO of Awakn Life Sciences Corp. stated: “When we launched the first clinic in the UK, our goal was to be able to provide greater access to medicine to those in need.  We are happy to transition Awakn Clinics London to Via, allowing us to focus on our efforts on research and development of therapeutics to treat addiction, especially our phase 3 trial of Ketamine assisted therapy for alcohol relapse prevention, where we are working with ten NHS trusts and the University of Exeter under a NIHR grant, with a goal to have the treatment available throughout the NHS. We look forward working closely with Via to gather additional real world evidence to support our ongoing research.”   

Adam Feldheim, Partner at Amitis Group stated: ‘’We are extremely happy to invest and partner alongside Via in this new venture. Via is a leader in providing addiction and mental health care in the UK and we are looking forward to working closely with them in bringing their expertise and standards of care to this new frontier.’’ 

This blog was originally published by Via. You can read the original post here.

DDN magazine is a free publication self-funded through advertising.

We are proud to work in partnership with many of the leading charities and treatment providers in the sector.

This content was created by Via

We value your input. Please leave a comment, you do not need an account to do this but comments will be moderated before they are displayed...